openPR Logo
Press release

Dr. Scott Siler to Discuss DILIsym Model in Rosa’s World-Wide Webinar Series, “Impact of Modeling & Simulation in Drug Development”

06-05-2012 08:49 PM CET | Science & Education

Press release from: Rosa and Co

Rosa Logo

Rosa Logo

Dr. Siler, will present “The DILIsym™ model and its application to hepatotoxicity testing in drug development” Webinar June 19, 2012

Rosa & Co. LLC today announced that Dr. Scott Siler, DILI-sim Consultant, will present a webinar “The DILIsym model and its application to hepatotoxicity testing in drug development” on Tuesday, June 19, 2012 at 1:00 - 2:00 pm EDT as part of Rosa’s ongoing monthly public webinar series. The purpose of the series, “Impact of Modeling & Simulation in Drug Development”, is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics, and other life science industries. This series is geared to illustrate the advantages and applicability of M&S in product discovery, development, and marketing programs.

According to Dr. Siler, “Drug induced liver injury (DILI) presents a substantial challenge to drug development, with DILI being responsible for multiple drugs being withdrawn from the market or receiving black box warnings at great cost. A mechanistic, multi-scale, mathematical model, DILIsym™, is being developed to assist in the safety characterization of compounds in in vitro to in vivo preclinical to first in human clinical development. Simulated humans, dogs, rats, and mice are included, with differences in biochemical variability amongst populations captured in SimPops™. The effects of reactive metabolites to elicit hepatotoxicity are included in v1A of the DILIsym™ model, with multiple drugs (e.g., acetaminophen) serving as exemplars for validation. Additional potential hepatotoxic participants, such as bile acids and mitochondria, are currently under development, broadening the range of compound types that can be evaluated with the model. Examples of how the DILIsym™ model can be used to support drug development safety assessment, experimental design, and increase understanding of DILI will be presented.”

Register for this free webinar at www.rosaandco.com/webinar. After registering, a confirmation email will be sent with directions for joining the webinar. More information about the webinar series, an archive of past webinars, and a list of future webinar speakers may be found at www.rosaandco.com/webinar.

About Rosa
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa’s staff have unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development and have completed hundreds of engagements with dozens of clients in multiple therapeutic areas. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals.

More information can be found online at http://www.rosaandco.com
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.

751 Laurel St., Ste. 127,
San Carlos, CA 94070

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dr. Scott Siler to Discuss DILIsym Model in Rosa’s World-Wide Webinar Series, “Impact of Modeling & Simulation in Drug Development” here

News-ID: 223926 • Views:

More Releases for DILI

Bullet Screen Video Sharing Site Market  Top Companies, Future Trends, Demand a …
"The Bullet Screen Video Sharing Site Market report is a valuable source of guidance and direction for companies and individuals interested in the Bullet Screen Video Sharing Site Market. Bullet Screen Video Sharing Site Market Report contains information about the company, such as growth potential, executive summary, growth drivers, price trend analysis, industry pitfall and difficulties, industry impact forces, and competitive landscape. Request Free sample Pages of this report https://www.infinitybusinessinsights.com/request_sample.php?id=680542 The most recent
Bullet Screen Video Sharing Site Market to Witness an Outstanding Growth by 2026
(Portland, United States): Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Bullet Screen Video Sharing Site Market in the latest research report added by Big Market Research. The recent research report on the global Bullet Screen Video Sharing Site Market presents the latest industry data and future trends, allowing you to recognize the products and end users driving
Italian Language Certificates issued by AIL and Scuola Leonardo da Vinci
Accademia Italiana di Lingua (AIL) is a professional association of schools, institutions and experts in the field of teaching Italian as a foreign language. The association guarantees its members high standards of education and represents a variety of institutions in Italy and abroad. Its main office is located in Florence, Italy. The Accademia Italiana di Lingua - http://www.scuolaleonardo.com/Italian-language-exam-courses.html - issues the first certificate of modern Italian that effectively tests the language
Reality TV Star Dylan Dilinjah From 'Making The Band' Signs New Record Deal With …
Dylan, star of Diddy’s MTV reality show for three seasons, has announced his signing to Indie label, Expat Records. Dylan Dilinjah who beat over 40,000 hopefuls to become one of the final 6 members to be selected to form the group ‘Daband’ on MTV’s hit TV show ‘Making The Band’ went on to achieve Platinum success and worldwide TV recognition. After the shows contractual end Dylan travelled on 2
Italian language Certifications with AIL
The AIL (Accademia Italiana di Lingua) is a non-profit association of schools and educators that was founded in 1984 to foster a program of certification in the Italian language. The certifications offered correspond to and reflect all the levels of communication recognized by the European Portfolio (ELP). Scuola Leonardo da Vinci, with centres in Florence, Milan, Rome and Siena, is a founding member of the AIL and offers preparatory courses for
Preparation Courses for AIL Exams
The Italian language school Leonardo da Vinci announces the opening of the preparation course for the winter session of Accademia Italiana di Lingua (AIL) exams on March 1st. Scuola Leonardo da Vinci is a founder member of AIL, the professional association of schools, institutions and experts in the field of teaching Italian as a foreign language (www.acad.it). The AIL exams (http://www.scuolaleonardo.com/Italian-language-exam-courses.html) will take place in all Leonardo da Vinci schools